ArticleFrontiers in psychology2025
The interplay between cognitive and psychological factors in subjective cognitive decline: contribution to the validation of a new screening battery.
Article in Frontiers in psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- More than Just a Game: A Longitudinal Pilot Study on the Outcome Effects of Home-Based Digital Cognitive Rehabilitation in Outpatients with Mild Cognitive Impairment.Brain sciences · 2026Article
- Why some minds bend, not break: an exploratory study of cognitive and psychological performance across levels of cognitive reserve in subjective cognitive decline.Frontiers in psychology · 2026Article
- Executive Functions and Subjective Cognitive Decline: The Moderating Role of Depressive Symptoms.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Subjective Cognitive Decline (SCD) is increasingly recognized as a potential early indicator of neurodegenerative disorders, yet its heterogeneous nature and lack of standardized screening tools complicate early detection and clinical management. This study aimed to comprehensively characterize a clinical SCD population and provide a preliminary contribution to the validation of a novel multidimensional screening battery, called MASCoD (Multidimensional Assessment of Subjective Cognitive Decline). Methods: A total of 59 individuals (69.36 ± 8.66, female: 71,2%) with self-reported SCD without objective cognitive impairment was recruited within two Centers for Cognitive Disorders and Dementia (CCDDs) in Northern Italy. Participants underwent a comprehensive assessment, including neurological assessment, neuropsychological testing, psychological screening, and administration of MASCoD. Convergent validity was assessed using the Cognitive Function Instrument (CFI), and internal consistency was evaluated too. Correlations between MASCoD subscales, depressive and anxious symptoms, and cognitive performance were examined, alongside comparisons between short and long forms of anxiety and depression measures (GAD and PHQ). Results: The sample showed preserved cognitive performance across all domains, consistent with SCD diagnostic criteria. Mild depressive symptoms were present and significantly associated with SCD, explaining up to around 10% of the variance in SCD measures. MASCoD Section B demonstrated good internal consistency (KR-20 = 0.782) and the entire tool shows moderate-to-strong convergent validity with the CFI. Notably, comparisons between PHQ-2/GAD-2 and their full-length versions indicated the brief tools may underestimate affective symptoms in this population. Conclusion: This study offers a detailed clinical and cognitive profile of an older SCD population, emphasizing the psychological dimensions of subjective complaints which should be evaluated into routine cognitive screening to proposed targeted preventive and rehabilitation interventions. The preliminary validation of MASCoD supports its potential as a reliable and multidimensional screening tool for early SCD detection. However, limitations such as small sample size, cross-sectional design, and cultural specificity necessitate further validation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.